<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223404</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00042696</org_study_id>
    <secondary_id>R21DA027894</secondary_id>
    <nct_id>NCT01223404</nct_id>
  </id_info>
  <brief_title>Nicotinic Modulation of the Default Network</brief_title>
  <official_title>Nicotinic Modulation of the Default Network of Resting Brain Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Maryland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many disorders where attentional problems are a hallmark, such as Alzheimer's disease and
      schizophrenia, display abnormal regulation of the so-called default network of resting brain
      function that maintains internally directed thought when the mind is free to wander. There is
      indication that nicotine may improve attention by aiding the deactivation of the default
      network, and this mechanism may be of therapeutic benefit for the above disease states. The
      current project aims at providing a proof of concept by demonstrating that nicotinic drugs
      modulate default network function. The nicotinic agonist nicotine is hypothesized to improve
      attention by facilitating the down-regulation of default network activity, and the nicotinic
      antagonist mecamylamine is hypothesized to impair attention by impeding the down-regulation
      of default network activity during attentional task performance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study only enrolls healthy non-smokers. Participants perform attention tasks while
      undergoing functional Magnetic Resonance Imaging on three separate days. Across the three
      days, three difference conditions are tested in a double-blind manner, in randomized order.
      In all test sessions, participants receive a skin patch and swallow a capsule. In one
      session, both are a placebo. In another, the patch is a low-dose nicotine patch, and the
      capsule is a placebo. In another session, the patch is a placebo and the capsule contains a
      low dose of mecamylamine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only the statistician performing the randomization and the pharmacist dispensing the drugs were aware which drug was given on which day.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reaction Time</measure>
    <time_frame>1 day</time_frame>
    <description>average reaction time on cognitive task performed in the MR scanner</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Signal Detection Performance</measure>
    <time_frame>1 day</time_frame>
    <description>Signal detection on cognitive tasks performed in the MR scanner. For the attention task, this represents the percentage of trials in which the participant responded when a signal was presented. In the working memory task (N-back task), this represents the percentage of all target sequences to which the participant responded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Default Network Activity</measure>
    <time_frame>1 day</time_frame>
    <description>Cognitive task-induced default network deactivation, measured by functional Magnetic Resonance Imaging. The default network was probed by five pre-defined ROIs per hemisphere. Task-induced deactivation was averaged across all ROIs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective State</measure>
    <time_frame>1 day</time_frame>
    <description>End-of-session subjective state is measured by the Profile of Mood States (POMS). We utilize &quot;Total Mood Disturbance&quot; (TMD) as a summary measure, derived by adding the total scores on the five negative mood scales (tension, depression, anger, fatigue, confusion) and subtracting the score on the one positive mood scale (vigor). The theoretical range of the TMD scale is -32 to 228, with negative values indicating less mood disturbance, i.e., a more positive emotional state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Bi-hourly: prior to patch application, 2 hours, 4 hours, and 6 hours after, and after the MRI scan (~8 hours after patch application)</time_frame>
    <description>Systolic blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Bi-hourly: prior to patch application, 2 hours, 4 hours, and 6 hours after, and after the MRI scan (~8 hours after patch application).</time_frame>
    <description>Diastolic blood pressure in mmHg.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Magnetic Resonance Imaging</condition>
  <condition>Cognition</condition>
  <condition>Nicotine</condition>
  <condition>Mecamylamine</condition>
  <arm_group>
    <arm_group_label>Placebo, Nicotine, Mecamylamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo 3 test sessions:
In the first session (&quot;placebo&quot;), a placebo patch and a placebo capsule is administered.
In the second session (&quot;nicotine&quot;), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.
In the third session (&quot;mecamylamine&quot;), a placebo patch and a mecamylamine capsule is administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine, Placebo, Mecamylamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo 3 test sessions:
In the first session (&quot;nicotine&quot;), a nicotine patch and a placebo capsule is administered.
In the second session (&quot;placebo&quot;), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.
In the third session (&quot;mecamylamine&quot;), a placebo patch and a mecamylamine capsule is administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Mecamylamine, Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo 3 test sessions:
In the first session (&quot;placebo&quot;), a placebo patch and a placebo capsule is administered.
In the second session (&quot;mecamylamine&quot;), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.
In the third session (&quot;nicotine&quot;), a nicotine patch and a placebo capsule is administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nicotine, Mecamylamine, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo 3 test sessions:
In the first session (&quot;nicotine&quot;), a nicotine patch and a placebo capsule is administered.
In the second session (&quot;mecamylamine&quot;), a placebo patch (7 mg/24 hrs) and a mecamylamine capsule is administered.
In the third session (&quot;placebo&quot;), a placebo patch and a placebo capsule is administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mecamylamine, Placebo, Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo 3 test sessions:
In the first session (&quot;mecamylamine&quot;), a placebo patch and a mecamylamine capsule is administered.
In the second session (&quot;placebo&quot;), a placebo patch (7 mg/24 hrs) and a placebo capsule is administered.
In the third session (&quot;nicotine&quot;), a nicotine patch and a placebo capsule is administered.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mecamylamine, Nicotine, Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants undergo 3 test sessions:
In the first session (&quot;mecamylamine&quot;), a placebo patch and a mecamylamine capsule is administered.
In the second session (&quot;nicotine&quot;), a nicotine patch (7 mg/24 hrs) and a placebo capsule is administered.
In the third session (&quot;placebo&quot;), a placebo patch and a placebo capsule is administered.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants are administered a placebo patch and a placebo capsule</description>
    <arm_group_label>Placebo, Nicotine, Mecamylamine</arm_group_label>
    <arm_group_label>Nicotine, Placebo, Mecamylamine</arm_group_label>
    <arm_group_label>Placebo, Mecamylamine, Nicotine</arm_group_label>
    <arm_group_label>Nicotine, Mecamylamine, Placebo</arm_group_label>
    <arm_group_label>Mecamylamine, Placebo, Nicotine</arm_group_label>
    <arm_group_label>Mecamylamine, Nicotine, Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotine</intervention_name>
    <description>Participants are administered a nicotine patch (7 mg/24 hrs) and a placebo capsule</description>
    <arm_group_label>Placebo, Nicotine, Mecamylamine</arm_group_label>
    <arm_group_label>Nicotine, Placebo, Mecamylamine</arm_group_label>
    <arm_group_label>Placebo, Mecamylamine, Nicotine</arm_group_label>
    <arm_group_label>Nicotine, Mecamylamine, Placebo</arm_group_label>
    <arm_group_label>Mecamylamine, Placebo, Nicotine</arm_group_label>
    <arm_group_label>Mecamylamine, Nicotine, Placebo</arm_group_label>
    <other_name>Nicotine CQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mecamylamine</intervention_name>
    <description>Participants are administered a placebo patch and a capsule containing 7.5 mg of mecamylamine</description>
    <arm_group_label>Placebo, Nicotine, Mecamylamine</arm_group_label>
    <arm_group_label>Nicotine, Placebo, Mecamylamine</arm_group_label>
    <arm_group_label>Placebo, Mecamylamine, Nicotine</arm_group_label>
    <arm_group_label>Nicotine, Mecamylamine, Placebo</arm_group_label>
    <arm_group_label>Mecamylamine, Placebo, Nicotine</arm_group_label>
    <arm_group_label>Mecamylamine, Nicotine, Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 21 through 50.

          -  Did not consume cigarettes, cigarillos, cigars, or other tobacco or
             nicotine-containing products more than 20 times in lifetime, and did not use any
             nicotine-containing product at all within the last two years.

          -  Normal or corrected to normal vision (at least 20/80).

        Exclusion Criteria:

          -  Presence of metal objects in the body, implanted electronic devices, or any other
             counter indication for MRI.

          -  Claustrophobia.

          -  Major psychiatric disorders including mood, anxiety or psychotic disorders.

          -  Cardiovascular or cerebrovascular disease, such as history of myocardial infarction,
             heart failure, angina, stroke, severe arrhythmias, or EKG abnormalities.

          -  Kidney or liver disease.

          -  Hypertension (resting systolic BP above 140 or diastolic above 85 mm Hg).

          -  Hypotension (resting systolic BP below 95 or diastolic below 60).

          -  Use of any prescription or over-the-counter drug other than supplements and birth
             control.

          -  History of or current neurological illnesses, such as stroke, seizures, dementia or
             organic brain syndrome.

          -  Learning disability, attention deficit disorder, or any other condition that impedes
             memory and attention.

          -  Glaucoma, organic pyloric stenosis, uremia or renal insufficiency.

          -  Prostatic hypertrophy, bladder neck obstruction or urethral stricture.

          -  Left-handed or ambidextrous.

          -  Pregnant as determined by urine test, or breast-feeding.

          -  History or current diagnosis of drug or alcohol abuse or dependence.

          -  IQ &lt; 85 as estimated by the WASI vocabulary subtest.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Britta Hahn, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institute on Drug Abuse, Intramural Research Program</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maryland Psychiatric Research Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hahn B, Ross TJ, Yang Y, Kim I, Huestis MA, Stein EA. Nicotine enhances visuospatial attention by deactivating areas of the resting brain default network. J Neurosci. 2007 Mar 28;27(13):3477-89.</citation>
    <PMID>17392464</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 13, 2010</study_first_submitted>
  <study_first_submitted_qc>October 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <results_first_submitted>May 2, 2017</results_first_submitted>
  <results_first_submitted_qc>January 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">January 25, 2018</results_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland</investigator_affiliation>
    <investigator_full_name>Britta Hahn</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>nicotine</keyword>
  <keyword>mecamylamine</keyword>
  <keyword>attention</keyword>
  <keyword>default network</keyword>
  <keyword>fMRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Mecamylamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Nicotine, Mecamylamine</title>
          <description>First session: Placebo patch and placebo capsule (filler: methylcellulose) Second session: Nicotine patch and Placebo capsule (filler: methylcellulose) Third session: Placebo patch and Mecamylamine capsule</description>
        </group>
        <group group_id="P2">
          <title>Nicotine, Placebo, Mecamylamine</title>
          <description>First session: Nicotine patch and placebo capsule (filler: methylcellulose) Second session: Placebo patch and Placebo capsule (filler: methylcellulose) Third session: Placebo patch and Mecamylamine capsule</description>
        </group>
        <group group_id="P3">
          <title>Placebo, Mecamylamine, Nicotine</title>
          <description>First session: Placebo patch and Placebo capsule (filler: methylcellulose) Second session: Placebo patch and Mecamylamine capsule Third session: Nicotine patch and Placebo capsule (filler: methylcellulose)</description>
        </group>
        <group group_id="P4">
          <title>Nicotine, Mecamylamine, Placebo</title>
          <description>First session: Nicotine patch and placebo capsule (filler: methylcellulose) Second session: Placebo patch and Mecamylamine capsule Third session: Placebo patch and Placebo capsule (filler: methylcellulose)</description>
        </group>
        <group group_id="P5">
          <title>Mecamylamine, Placebo, Nicotine</title>
          <description>First session: Placebo patch and Mecamylamine capsule Second session: Placebo patch and Placebo capsule (filler: methylcellulose) Third session: Nicotine patch and Placebo capsule (filler: methylcellulose)</description>
        </group>
        <group group_id="P6">
          <title>Mecamylamine, Nicotine, Placebo</title>
          <description>First session: Placebo patch and Mecamylamine capsule Second session: Nicotine patch and Placebo capsule (filler: methylcellulose) Third session: Placebo patch and Placebo capsule (filler: methylcellulose)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Third Intervention (1 Day)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Non-compliance (slept)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>21 healthy non-smokers were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants in each of the six arms received all three interventions (placebo, nicotine, mecamylamine).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Reaction Time</title>
        <description>average reaction time on cognitive task performed in the MR scanner</description>
        <time_frame>1 day</time_frame>
        <population>18 healthy male and female adult non-smokers. Only study completers are included, due to the within-subject design.</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Placebo</title>
            <description>A placebo patch and a placebo capsule are administered.</description>
          </group>
          <group group_id="O2">
            <title>Intervention: Nicotine</title>
            <description>A nicotine patch and a placebo capsule is administered.</description>
          </group>
          <group group_id="O3">
            <title>Intervention: Mecamylamine</title>
            <description>A placebo patch and a mecamylamine capsule are administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Reaction Time</title>
          <description>average reaction time on cognitive task performed in the MR scanner</description>
          <population>18 healthy male and female adult non-smokers. Only study completers are included, due to the within-subject design.</population>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Attention task reaction time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="512" lower_limit="485" upper_limit="539"/>
                    <measurement group_id="O2" value="492" lower_limit="464" upper_limit="520"/>
                    <measurement group_id="O3" value="524" lower_limit="489" upper_limit="559"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Working memory task reaction time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="541" lower_limit="516" upper_limit="566"/>
                    <measurement group_id="O2" value="533" lower_limit="508" upper_limit="558"/>
                    <measurement group_id="O3" value="573" lower_limit="537" upper_limit="609"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Signal Detection Performance</title>
        <description>Signal detection on cognitive tasks performed in the MR scanner. For the attention task, this represents the percentage of trials in which the participant responded when a signal was presented. In the working memory task (N-back task), this represents the percentage of all target sequences to which the participant responded.</description>
        <time_frame>1 day</time_frame>
        <population>Healthy adult non-smokers (only study completers).</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Placebo</title>
            <description>A placebo patch and a placebo capsule are administered.</description>
          </group>
          <group group_id="O2">
            <title>Intervention: Nicotine</title>
            <description>A nicotine patch and a placebo capsule are administered.</description>
          </group>
          <group group_id="O3">
            <title>Intervention: Mecamylamine</title>
            <description>A placebo patch and a mecamylamine capsule are administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Signal Detection Performance</title>
          <description>Signal detection on cognitive tasks performed in the MR scanner. For the attention task, this represents the percentage of trials in which the participant responded when a signal was presented. In the working memory task (N-back task), this represents the percentage of all target sequences to which the participant responded.</description>
          <population>Healthy adult non-smokers (only study completers).</population>
          <units>percentage of all targets</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Attention task correct identifications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4" lower_limit="81.4" upper_limit="91.4"/>
                    <measurement group_id="O2" value="93.8" lower_limit="90.1" upper_limit="97.5"/>
                    <measurement group_id="O3" value="85.2" lower_limit="79.7" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Working memory task correct detections</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.6" lower_limit="88.4" upper_limit="90.8"/>
                    <measurement group_id="O2" value="95.5" lower_limit="94.9" upper_limit="96.1"/>
                    <measurement group_id="O3" value="88.6" lower_limit="87.9" upper_limit="89.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Default Network Activity</title>
        <description>Cognitive task-induced default network deactivation, measured by functional Magnetic Resonance Imaging. The default network was probed by five pre-defined ROIs per hemisphere. Task-induced deactivation was averaged across all ROIs.</description>
        <time_frame>1 day</time_frame>
        <population>Healthy non-smokers (only study completers).</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Placebo</title>
            <description>A placebo patch and a placebo capsule is administered.</description>
          </group>
          <group group_id="O2">
            <title>Intervention: Nicotine</title>
            <description>A nicotine patch and a placebo capsule are administered.</description>
          </group>
          <group group_id="O3">
            <title>Intervention: Mecamylamine</title>
            <description>A placebo patch and a mecamylamine capsule are administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Default Network Activity</title>
          <description>Cognitive task-induced default network deactivation, measured by functional Magnetic Resonance Imaging. The default network was probed by five pre-defined ROIs per hemisphere. Task-induced deactivation was averaged across all ROIs.</description>
          <population>Healthy non-smokers (only study completers).</population>
          <units>percentage of task-induced signal change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.29" lower_limit="-0.41" upper_limit="-0.17"/>
                    <measurement group_id="O2" value="-0.24" lower_limit="-0.39" upper_limit="-0.09"/>
                    <measurement group_id="O3" value="-0.21" lower_limit="-0.33" upper_limit="-0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective State</title>
        <description>End-of-session subjective state is measured by the Profile of Mood States (POMS). We utilize &quot;Total Mood Disturbance&quot; (TMD) as a summary measure, derived by adding the total scores on the five negative mood scales (tension, depression, anger, fatigue, confusion) and subtracting the score on the one positive mood scale (vigor). The theoretical range of the TMD scale is -32 to 228, with negative values indicating less mood disturbance, i.e., a more positive emotional state.</description>
        <time_frame>1 day</time_frame>
        <population>Healthy non-smokers (only study completers).</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Placebo</title>
            <description>A placebo patch and a placebo capsule are administered.</description>
          </group>
          <group group_id="O2">
            <title>Intervention: Nicotine</title>
            <description>A nicotine patch and a placebo capsule are administered.</description>
          </group>
          <group group_id="O3">
            <title>Intervention: Mecamylamine</title>
            <description>A placebo patch and a mecamylamine capsule were administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective State</title>
          <description>End-of-session subjective state is measured by the Profile of Mood States (POMS). We utilize &quot;Total Mood Disturbance&quot; (TMD) as a summary measure, derived by adding the total scores on the five negative mood scales (tension, depression, anger, fatigue, confusion) and subtracting the score on the one positive mood scale (vigor). The theoretical range of the TMD scale is -32 to 228, with negative values indicating less mood disturbance, i.e., a more positive emotional state.</description>
          <population>Healthy non-smokers (only study completers).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" lower_limit="-12.3" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-9.9" lower_limit="-15.4" upper_limit="-4.4"/>
                    <measurement group_id="O3" value="-5.8" lower_limit="-12" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <description>Systolic blood pressure (mmHg)</description>
        <time_frame>Bi-hourly: prior to patch application, 2 hours, 4 hours, and 6 hours after, and after the MRI scan (~8 hours after patch application)</time_frame>
        <population>Healthy non-smokers</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Placebo</title>
            <description>A placebo patch and a placebo capsule were administered.</description>
          </group>
          <group group_id="O2">
            <title>Intervention: Nicotine</title>
            <description>A nicotine patch and a placebo capsule were administered.</description>
          </group>
          <group group_id="O3">
            <title>Intervention: Mecamylamine</title>
            <description>A placebo patch and a mecamylamine capsule were administered.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Systolic blood pressure (mmHg)</description>
          <population>Healthy non-smokers</population>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.2" spread="11.4"/>
                    <measurement group_id="O2" value="120.9" spread="16.7"/>
                    <measurement group_id="O3" value="119.3" spread="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.1" spread="11.9"/>
                    <measurement group_id="O2" value="114.3" spread="10.7"/>
                    <measurement group_id="O3" value="112.3" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.1" spread="16.7"/>
                    <measurement group_id="O2" value="119.1" spread="9.9"/>
                    <measurement group_id="O3" value="114.4" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.3" spread="12.9"/>
                    <measurement group_id="O2" value="122.7" spread="12.7"/>
                    <measurement group_id="O3" value="118.2" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-scan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.7" spread="16.1"/>
                    <measurement group_id="O2" value="127.4" spread="9.8"/>
                    <measurement group_id="O3" value="121.5" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <description>Diastolic blood pressure in mmHg.</description>
        <time_frame>Bi-hourly: prior to patch application, 2 hours, 4 hours, and 6 hours after, and after the MRI scan (~8 hours after patch application).</time_frame>
        <population>Healthy non-smokers (only study completers).</population>
        <group_list>
          <group group_id="O1">
            <title>Intervention: Placebo</title>
            <description>Placebo patch and placebo capsule.</description>
          </group>
          <group group_id="O2">
            <title>Intervention: Nicotine</title>
            <description>Nicotine patch and placebo capsule.</description>
          </group>
          <group group_id="O3">
            <title>Intervention: Mecamylamine</title>
            <description>Placebo patch and mecamylamine capsule.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Diastolic blood pressure in mmHg.</description>
          <population>Healthy non-smokers (only study completers).</population>
          <units>mmHG</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="8.0"/>
                    <measurement group_id="O2" value="71.6" spread="10.0"/>
                    <measurement group_id="O3" value="73.4" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 hours post patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" spread="10.0"/>
                    <measurement group_id="O2" value="71.9" spread="9.9"/>
                    <measurement group_id="O3" value="73.2" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 hours post patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.7" spread="9.7"/>
                    <measurement group_id="O2" value="71.1" spread="7.9"/>
                    <measurement group_id="O3" value="72.4" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours post patch</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" spread="6.6"/>
                    <measurement group_id="O2" value="75.3" spread="5.8"/>
                    <measurement group_id="O3" value="75.2" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-scan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.3" spread="5.4"/>
                    <measurement group_id="O2" value="81.1" spread="5.7"/>
                    <measurement group_id="O3" value="79.6" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 day (on each of separate 3 test days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intervention: Placebo</title>
          <description>Participants receive a placebo patch and a placebo capsule.</description>
        </group>
        <group group_id="E2">
          <title>Intervention: Nicotine</title>
          <description>Participants receive a nicotine patch and a placebo capsule.</description>
        </group>
        <group group_id="E3">
          <title>Intervention: Mecamylamine</title>
          <description>Participants receive a placebo patch and a mecamylamine capsule.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Britta Hahn</name_or_title>
      <organization>University of Maryland School of Medicine</organization>
      <phone>4104026112</phone>
      <email>bhahn@mprc.umaryland.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

